Pipeline | Myriad Genetics, Inc.

Myriad and Abbott Enter Into Cooperative Agreement

Myriad Genetics Licenses Novel Technology From Chronix Biomedical

Myriad Genetics and BioMarin Pharmaceutical Inc. Enter Into Agreement

Myriad Announces Diabetes Collaboration With Sanofi

Myriad Genetics' HRD Test Predicts Response to Platinum Therapy in Triple-Negative Breast Cancer

Myriad's HRD Score Detects Loss of DNA Repair Function in Ovarian Cancer

Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement

Myriad Study Finds High Prevalence of Mutations in the PMS2 Gene

Myriad and Cephalon Enter Into Companion Diagnostic Agreement

Myriad's HRD Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study

Investor Relations Contact

Matt Scalo
801.584.3532
matt.scalo@myriad.com

Myriad and Abbott Enter Into Cooperative Agreement

Myriad Genetics Licenses Novel Technology From Chronix Biomedical

Myriad Genetics and BioMarin Pharmaceutical Inc. Enter Into Agreement

Myriad Announces Diabetes Collaboration With Sanofi

Myriad Genetics' HRD Test Predicts Response to Platinum Therapy in Triple-Negative Breast Cancer

Myriad's HRD Score Detects Loss of DNA Repair Function in Ovarian Cancer

Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement

Myriad Study Finds High Prevalence of Mutations in the PMS2 Gene

Myriad and Cephalon Enter Into Companion Diagnostic Agreement

Myriad's HRD Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study

Investor Relations Contact

Stock Quote